India is an important market for many multinational pharmaceutical, biotech or medical device companies. But it is also a challenging one.
Join Martina Rozumberkova for a conversation with Sushmit Bhattacharya about challenges facing multinational pharmaceutical companies operating in India, from important regulatory changes, including the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, to emerging fraud schemes, including fraud in the Government e-Marketplace (GeM) and retailer incentive schemes.
In order to play this media, we need your consent to add cookies to your device. Do you accept these cookies? Find out More.
Listen and subscribe to In Re:
|
|